The short answer
PlushCare is our top pick for insurance maximizers. Score 7.2 of 10. In-network with most major commercial plans, runs PA on Wegovy and Zepbound, and the PCPs have written hundreds of GLP-1 prescriptions. If your plan covers it, you can be on a $25 to $50 copay within 4 to 6 weeks.
The short version
Insurance coverage of GLP-1 weight loss medication expanded substantially through 2024 and 2025. Most commercial PPO plans now cover Wegovy or Zepbound with prior authorization criteria that include BMI 30 (or 27 with comorbidity), documented lifestyle modification and (on some plans) step-therapy through an older anti-obesity medication. The PA itself is paperwork. Programs vary by an order of magnitude in how well they handle it. The right program for an insured patient is one whose prescribers know your specific plan's PA reviewer and write the visit notes that get approved on first submission, not on appeal three months later.
What we considered
- In-network with major commercial PPO plans (Aetna, BCBS, Cigna, UHC)
- Runs PA on Wegovy or Zepbound through the plan's PBM
- Documents comorbidities and step-therapy correctly for first-pass approval
- Verifies coverage before billing your card (transparent fallback if denied)
- PA approval rate and time-to-submission
Top pick: PlushCare
PlushCare is in-network with most commercial PPOs, runs PA fast and handles the comorbidity documentation primary-care PA reviewers want to see. The cleanest insurance-maximizing path if your plan covers GLP-1 weight loss with standard PA criteria.
Read the full PlushCare review →
Why PlushCare won this category
PlushCare is one of the few telehealth programs in our chart that is genuinely in-network with major commercial PPO plans, not just willing to take your card. They bill your insurance directly for the visit, run the PA on Wegovy or Zepbound through your plan's pharmacy benefit manager, and handle the comorbidity documentation that PA reviewers want to see. If your plan covers GLP-1 weight loss, the path from intake to a $25 to $50 monthly copay typically lands in 4 to 6 weeks.
The PCPs are the differentiator. PlushCare employs primary-care doctors, not single-condition obesity-medicine specialists, which sounds like a downside but is actually the right fit for the insurance pathway. Commercial PA reviewers want to see comorbidities documented in a primary-care visit note: hypertension, dyslipidemia, sleep apnea, prediabetes. A PCP sees those naturally as part of a normal workup. An obesity-medicine specialist will often surface them too, but at higher cost.
Speed matters for insured patients in ways it doesn't for cash-pay. The PA review window is typically 7 to 14 business days, and a denied PA triggers an appeal that adds another 4 to 8 weeks. PlushCare's median time from intake to PA submission is under 24 hours. If your plan approves the first PA, you're filling a script at the pharmacy within 3 to 4 weeks of first contact. If your plan denies it, you know early and can pivot to appeal or cash-pay without months of paid waiting.
The fallback path is honest. If your insurance check at intake shows your plan doesn't cover GLP-1 weight loss, PlushCare tells you before billing your card. The $19.99 per month membership stays cheap, and the cash-pay route through their network is transparent. Programs that hide the insurance-check failure until after billing your card are the ones to avoid; PlushCare is not one of them.
Who this pick isn't for
PlushCare is not the right pick if your insurance plan has a strict step-therapy requirement that demands documented failure on phentermine or other anti-obesity medications first. Some Cigna and UHC plans require this, and the visit-note structure to satisfy step-therapy is more specialized than PlushCare's general PCP model handles. Form Health's obesity-medicine specialists write stronger step-therapy letters; the higher cost is justified if your plan requires that path.
PlushCare is also not the right pick if you have Medicare and need the cardiovascular-indication coding for Wegovy. Medicare Part D's coverage of Wegovy is restricted to patients with established cardiovascular disease (post-MI, post-stroke, symptomatic PAD) and the prescription must be coded for CV risk reduction, not weight loss. Most telehealth PCPs don't know the CV-indication coding well; Knownwell and Form Health do.
And PlushCare doesn't fit if your insurance check shows no coverage and your real preference was insurance-billed all along. In that case, don't pay the membership fee. Look at the cash-pay picks (Mochi, Henry, Hims, Ro) and accept that the cash-pay math is your reality. PlushCare can convert to cash-pay, but their cash-pay path is more expensive than the programs that specialize in cash-pay.
Runner-up: Form Health
Form Health is the runner-up specifically for step-therapy or appeal cases: their board-certified obesity-medicine specialists write the strongest PA letters in our chart, with the highest documented first-pass approval rate.
Read the full Form Health review →
Top 3 compared
| Program | Score | Starts from | Lock-in | Time to Rx |
|---|---|---|---|---|
| PlushCare | 7.2 | $19.99/mo | Month-to-month | 1 day |
| Form Health | 7.6 | $299/mo | Month-to-month | 7 days |
| Knownwell | 7.5 | Insurance-billed | Month-to-month | 14 days |
Other strong picks
Frequently asked
How long does prior authorization actually take?
Typical commercial PA review is 7 to 14 business days from submission. If your plan requires step-therapy or has additional documentation requirements, expect 14 to 21 days. PA denials trigger an appeal process that adds 4 to 8 weeks. The fastest insurance path to filled script is around 3 to 4 weeks from first intake; the median is 4 to 6 weeks.
What if my plan covers Wegovy but not Zepbound, or vice versa?
Most plans cover one or the other on formulary, sometimes both. Wegovy (semaglutide) is on more formularies than Zepbound (tirzepatide) because Wegovy launched 2 years earlier and has had time to land on commercial PBM contracts. If your plan covers only one, the prescriber writes for the covered drug. Switching to the non-formulary drug requires either a formulary exception (rarely granted) or cash-pay.
What does my insurance actually cost me out of pocket?
If your plan covers GLP-1 weight loss with PA approved, expect a Tier 3 or Tier 4 specialty copay: typically $25 to $100 per month for Tier 3, $50 to $300 for Tier 4. Some employer plans waive the copay for obesity treatment under preventive care benefits. Check your plan's specific Tier copay schedule for GLP-1s. The membership fee at PlushCare ($19.99 per month) is additional.
Can I use HSA or FSA for the medication?
Yes. GLP-1 medications prescribed for an FDA-approved indication (Wegovy for weight loss with BMI 30+, or BMI 27+ with comorbidity; Ozempic and Mounjaro for type 2 diabetes; Zepbound for weight loss with similar BMI criteria) are HSA and FSA eligible. The membership fees at telehealth programs are usually also eligible. Save the receipts and the prescription documentation.
What's the strongest plan type for GLP-1 coverage?
Federal Employees Health Benefits (FEHB) plans, especially the BCBS FEP plan, have the most generous GLP-1 weight-loss coverage. Self-insured large-employer plans are next strongest because the employer chose the formulary. State Medicaid is the weakest for weight loss (almost never covered). Medicare Advantage varies; standalone Medicare Part D covers Wegovy only for CV indication, never for weight loss alone.
What if my PA gets denied?
You have three options: appeal the denial (success rate around 40 to 50 percent on first appeal with proper documentation), pivot to cash-pay through the same or a different program, or switch insurance during open enrollment to a plan that covers GLP-1. PlushCare and Form Health both handle appeals; Form Health's appeal letters are stronger. Our PA step-by-step covers the appeal process.
Should I disclose my comorbidities at intake?
Yes, all of them. The PA approval depends on documented comorbidities (hypertension, dyslipidemia, sleep apnea, prediabetes, T2D, CV disease, MASH/NAFLD, PCOS). Patients who underreport comorbidities at intake often get denied for not meeting BMI 27 plus comorbidity criteria when they actually qualified. Bring lab results, blood pressure readings and any existing diagnoses to the visit.
Sources
- CMS: Medicare Part D coverage of Wegovy for cardiovascular risk reduction (March 2024 NCD)
- Wilding JP, et al. STEP-1: semaglutide in overweight or obesity. NEJM 2021
- Jastreboff AM, et al. SURMOUNT-1: tirzepatide for obesity. NEJM 2022
- AHFS Drug Information: semaglutide and tirzepatide PA criteria across major commercial PBMs
Related
